Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.57 |
| ▸ | CA12 | O43570 | 8/20 | 0.57 |
| ▸ | CA9 | Q16790 | 8/20 | 0.57 |
| ▸ | CA1 | P00915 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726371 | 0.89 | CA2 (0.62) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6732794 | 0.88 | CA2 (0.54) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6723927 | 0.85 | PTGS2 (0.66) | PTGS2PTGS1 | |
| SCHEMBL6721528 | 0.84 | PTGS2 (0.60) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6733384 | 0.83 | CA12 (0.64) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6725652 | 0.82 | PTGS2 (0.54) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6721587 | 0.82 | CA2 (0.58) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6724754 | 0.81 | PTGS2 (0.60) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6726391 | 0.81 | PTGS2 (0.61) | CA2PTGS2PTGS1CA12CA9 | |
| SCHEMBL6725911 | 0.81 | PTGS2 (0.62) | CA2PTGS2PTGS1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2004-08-12 | — | — | US | disclosed |
| US-6677488-B2 | AS AN EXAMPLE, 4-(4,5-DIFLUORO-2-(3-CHLORO-4-FLUOROPHENYL) PHENYLBENZENESULFONAMIDE; ANTIARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; PROSTAGLANDIN INHIBITORS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-11-14 | — | — | US | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | CA2 2743/4885PTGS2 379/4885PTGS1 292/4885 |
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | CA2 2743/4885PTGS2 379/4885PTGS1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.